Mechanism of action and pharmacological research progress of fezolinetant

Fezolinetant is a selective neurokinin 3 receptor (NK3R) antagonist, primarily used to treat moderate to severe vasomotor symptoms (VMS), such as hot flashes and night sweats, in postmenopausal women. Its unique mechanism of action brings the drug a new treatment direction in the field of female menopause management, especially providing non-hormonal alternative options for patients who are unable or unwilling to use hormone replacement therapy (HRT).

In terms of pharmacological mechanism, Fezonatan regulates the neural pathways responsible for body temperature control by blocking the binding of neurokinin B (NKB) and its receptor NK3R in the hypothalamus. During menopause, due to the decrease in estrogen levels, the NKB-NK3R pathway becomes abnormally active, resulting in increased sensitivity of the body temperature regulation center, leading to symptoms such as hot flashes. Fezonatant can inhibit the over-excitability of this pathway and alleviate the frequency and intensity of hot flashes from the source. It is a new treatment method that targets the regulation of the central nervous system.

In terms of clinical research, Fezolinetant has completed multiple critical III clinical trials (such as the SKYLIGHT series of studies). The results show that it has a significant effect in reducing the number of hot flashes and improving the severity of symptoms, and has a rapid onset of action. Significant improvements can generally be observed within a few days of taking the medicine. In addition, the drug has good safety, no serious hormonal side effects have been found, and it will not cause irritation to the endometrium or breast tissue, providing a safer long-term management solution for menopausal women.

Currently, Fezonatant has been approved by the FDA for the treatment of menopause-related VMS in the United States, and is gradually applying for marketing authorization in other markets around the world. Researchers are also exploring its potential in other diseases related to hormone fluctuations, such as polycystic ovary syndrome and sex hormone-dependent mental disorders. As the first NK3R antagonist to enter the market, fizonatan represents a new stage in menopausal treatment from traditional hormone therapy to targeting neuromodulatory mechanisms, and has broad application prospects.

Reference materials:https://www.drugs.com/